First new treatment in more than 50 years
3/21/2011
The U.S. Food and Drug Administration has approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.
Please read more in the FDA's press release and get some more information on the LFA's website.